Some investors asked on the investor interaction platform: Zhejiang Xianju Pharmaceutical Co.Ltd(002332) as the largest manufacturer of steroidal drugs in China, and CETOL is the largest manufacturer of steroidal intermediate API in China, will CETOL extend downstream preparations and other finished drugs form a direct competitive relationship with Xianju? What are the advantages of your company in R & D technology?
Shandong Sito Bio-Technology Co.Ltd(300583) (300583. SZ) said on the investor interaction platform on January 5 that the company adopts a differentiated competition strategy in the selection of preparation products. In terms of the current product layout, there is no strong competitive relationship with the company’s existing downstream customers. The company unswervingly adheres to the strategy of the whole industrial chain layout. The core technologies formed through years of R & D and accumulation cover biological fermentation, enzyme transformation, chemical synthesis and other links. At the same time, the Italian lisapharma company acquired by the company in the early stage has rich product and technical reserves in preparation, which also increases the thickness of the company’s R & D.
(Daily Economic News)
